|
Elabscience Biotechnology
β2 ar  β2 Ar, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/result/β2 ar/product/Elabscience Biotechnology Average 90 stars, based on 1 article reviews
β2 ar - by Bioz Stars,
2026-05
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
doi: 10.1016/j.biopha.2021.112411
Figure Lengend Snippet: Fig. 2. Relative mRNA expression of cardiac β1-AR, β2-AR, GRK2, and GRK3 in rats treated with P. Note a statistically significant decrease of GRK2 mRNA levels in rats treated with paroxetine, 10 mg/kg/day p.o. Data represent the mean of five rats ± SEM. *p < 0.05 vs. control group (One-way ANOVA fol lowed by Tukey’s multiple comparisons). β-AR, beta-adrenergic receptor; GRK, G protein-coupled receptor kinase.
Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200),
Techniques: Expressing, Control
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
doi: 10.1016/j.biopha.2021.112411
Figure Lengend Snippet: Fig. 6. Representative photomicrographs of immunohistochemical analysis showing β1-AR and β2-AR. Note decreased immunoreactivity in DOX+P rats. β-AR, beta- adrenergic receptor; DOX, doxorubicin; P, paroxetine.
Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200),
Techniques: Immunohistochemical staining
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Article Title: Paroxetine mitigates cardiac remodelling by doxorubicin and increases survival.
doi: 10.1016/j.biopha.2021.112411
Figure Lengend Snippet: Fig. 7. Relative mRNA expression of cardiac β-1 AR, β-2 AR, GRK2, GRK3, ARRB1, and ARRB2 in DOX- and DOX+P -treated rats. Note a statistically significant increase of GRK2 and GRK3 mRNA levels in DOX-HCM rats, a statistically significant increase of β1-AR and β2-AR mRNA levels, and a statistically significant decrease of GRK2 and GRK3 mRNA levels in DOX+P-treated rats. Data represent the mean of at least 7 rats ± SEM.*p < 0.05; * *p < 0.01 vs. control group, †p < 0.05; ††p < 0.01 vs. DOX-HCM, #p < 0.05; ##p < 0.01 vs. DOX-DCM (One-way ANOVA followed by Tukey’s multiple comparisons or Kruskal–Wallis ANOVA followed by Mann–Whitney U test for nonparametric data). β-AR, beta-adrenergic receptor; DCM, dilated cardiomyopathy; DOX, doxorubicin; HCM, hypertrophic cardiomy opathy; GRK, G protein-coupled receptor kinase; P, paroxetine.
Article Snippet: Immunohistochemistry was performed manually on the 5 μm-thick sections, according to the manufacturer’s instructions using the specific monoclonal antibodies against CD68 (DAKO, clone PG-M1, dilution 1:50) Leukocyte common antigen LCA IHC (DAKO, clone 2B11 +PD7/26, dilution 1:200), β1-AR (Elabscience®, ADRB1 polyclonal antibody, dilution 1:200),
Techniques: Expressing, Control, MANN-WHITNEY